Advertisement

Relationship between immune and behavioral measures in schizophrenia

  • D. P. van Kammen
  • C. G. McAllister
  • M. E. Kelley
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Abstract

Schizophrenia, which is a chronic but episodic disorder of unknown etiology, shares immunological features with organ specific autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis and insulin-dependent diabetes mellitus. However, recent studies have raised the issue as to whether the reported immune disturbances in schizophrenia may be the result of a stress-induced dysregulation of CNS cytokine production, rather than a permanent immunological disorder, i.e., autoimmunity.

Keywords

Negative Symptom Haloperidol Treatment Organ Specific Autoimmune Disease Episodic Disorder Negative Symp 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–794PubMedGoogle Scholar
  2. Brown R, Li Z, Vriend CY, Nirula R, Janz L, Falk J, Nance DM, Dyck DG, Greenberg AH (1991) Suppression of splenic macrophage interleukin-1 secretion following intracerebroventricular injection of interleukin-1β: evidence of pituitary-adrenal and sympathetic control. Cell Immunol 132: 84 – 93PubMedCrossRefGoogle Scholar
  3. Bunney Jr WE, Hamburg DA (1963) Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 9: 280 – 294PubMedGoogle Scholar
  4. Carpenter Jr WT, Heinrichs DW, Wagman AMI (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145: 578 – 583PubMedGoogle Scholar
  5. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann Intern Med 107: 293 – 300PubMedGoogle Scholar
  6. Denicoff KD, Durkin TM, Lotze MT, Quinlan PE, Davis CL, Listwak SJ, Rosenberg SA, Rubinow DR (1989) The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69: 402 – 410PubMedCrossRefGoogle Scholar
  7. Lapchek PA, Araujo DM, Quirion R, Beaudet A (1991) Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neurosci 44: 173 – 184CrossRefGoogle Scholar
  8. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152: 1291 – 1297PubMedGoogle Scholar
  9. Merrill JE (1990) Interleukin-2 effects in the central nervous system. Ann NY Acad Sci 594: 188 – 199PubMedCrossRefGoogle Scholar
  10. Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14: 1 – 10PubMedCrossRefGoogle Scholar
  11. Ramírez F, Fowell DJ, Puklavec M, Simmonds S, Mason D (1996) Glucocorticoids promote a Th2 cytokine response by CD4+ T cells in vitro. J Immunol 156: 2406 – 2412PubMedGoogle Scholar
  12. Rook GAW, Hernandez-Panclo R, Lightman SL (1994) Hormones, peripherally acti-vated prohormones and regulation of the Thl/Th2 balance. Immunol Today 15: 301 – 303PubMedCrossRefGoogle Scholar
  13. Savino W, Dardenne M (1995) Immune-neuroendocrine interactions. Immunol Today 16: 318 – 321PubMedCrossRefGoogle Scholar
  14. Tandon R, Jibson MD, Taylor SF, DeQuardo JR (1995) Conceptual models of the relationship between positive and negative symptoms. In: Shriqui L, Nasrallah HA (eds) Contemporary issues in the treatment of schizophrenia. American Psychiatric Press, Washington DC, pp 109 – 124Google Scholar
  15. Tarazona R, González-García A, Zamzami N, Marchetti P, Frechin N, Gonzalo JA, Ruiz-Gayo M, van Rooijen N, Martínez-A. C, Kroemer G (1995) Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 154: 861 – 870Google Scholar
  16. van Kammen DP, Ågren H, Yao JK, O’Connor DT, Gurklis JA, Peters JL (1994) Nor-adrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 151: 379 – 384PubMedGoogle Scholar
  17. van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL (1995) Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry 52: 673 – 678PubMedGoogle Scholar
  18. van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL (1996) Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia. Neuropsychopharmacology 14:275–283PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • D. P. van Kammen
    • 1
    • 2
  • C. G. McAllister
    • 1
    • 2
  • M. E. Kelley
    • 1
  1. 1.Veterans Affairs Medical CenterUniversity of Pittsburgh, School of MedicinePittsburghUSA
  2. 2.Western Psychiatric Institute and ClinicUniversity of Pittsburgh, School of MedicinePittsburghUSA

Personalised recommendations